Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab

Journal of Neuroimmunology

Volumn 243, Issue 1-2, 2012, Pages 103-105

  Mulero, Patricia ^a   Caminero, Ana Belén ^b   Neri Crespo, Ma José ^a   Fernández Herranz, Rosario ^a   Téllez Lara, Nieves ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL PROVINCIAL DE ÁVILA   (Spain)

Author keywords

Monoclonal antibody; MS; Multiple sclerosis; Natalizumab; TB; Tuberculosis

Indexed keywords

ISONIAZID; NATALIZUMAB;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LATENT TUBERCULOSIS; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPAIN; THORAX RADIOGRAPHY; UPREGULATION; VIRUS ACTIVATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SPAIN; TUBERCULOSIS; YOUNG ADULT;

EID: 84856966703     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.12.009     Document Type: Article

References (15)

1. Aberra F.N., Stettler N., Brensinger C., Lichtenstein G.R., Lewis J.D. Risk for active tuberculosis in inflammatory bowel disease patients. Clin. Gastroenterol. Hepatol. 2007, 5(9):1070-1075. Sep.
2. Biogen Indec, post-marketing data on file.
3. Carmona L., Gómez-Reino J.J., Rodríguez-Valverde V., Montero D., Pascual-Gómez E., Martin Mola E., Carreño L., Figueroa M. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumour necrosis factor antagonists. Arthritis Rheum. 2005, 52(6):1766-1772. Jun.
4. Carmona L., Hernández-García C., Vadillo C., Pato E., Balsa A., González-Alvaro I., Belmonte M.A., Tena X., Sanmartí R., EMECAR Study Group Increased risk of tuberculosis in patients with rheumatoid arthritis. J. Rheumatol. 2003, 30(7):1436-1439. Jul.
5. European Medicines Agency http://www.emea.europa.eu.
6. Feng C., Britton W.J., Palendira U., Groat N., Briscoe H., Bean A. Up-regulation of VCAM-1 and differential expansion of β integrin-expressing T lymphocytes are associated with immunity to pulmonary Mycobacterium tuberculosis infection. J. Immunol. 2000, 164(9):4853-4860. May.
7. Gan J., Manadan A.M., Sequiera W., Block J.A. Tuberculosis infections and tumor necrosis factor alpha antagonists. Am. J. Ther. 2011, 124:1779-1782.
8. Gold R., Jawad A., Miller D.H., Henderson D.C., Fassas A., Fierz W., Hartung H.P. Expert opinion: guidelines for the use of natalizumab in mutiple sclerosis patients previously treated with immunomodulating therapies. J. Neuroimmunol. 2007, 187(1-2):156-158. Jul.
9. Gomez-Reino J.J., Carmona L., Rodríguez Valverde V., Martín Mola E., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active surveillance report. Arthritis Rheum. 2003, 48(8):2122-2127. BIOBADASER Group, Aug.
10. Kappos L., Bates D., Edan G., Eraksoy M., Garcia-Merino A., Grigoriadis N., Hartung H.P., Havrdová E., Hillert J., Hohlfeld R., Kremenchutzky M., Lyon-Caen O., Miller A., Pozzilli C., Ravnborg M., Saida T., Sindic C., Vass K., Clifford D.B., Hauser S., Major E.O., O'Connor P.W., Weiner H.L., Clanet M., Gold R., Hirsch H.H., Radü E.W., Sørensen P.S., King J. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011, 10(8):745-758. Aug.
11. Rose D.N. Benefits of screening for latent Mycobacterium tuberculosis infection. Arch. Intern. Med. 2000, 160(10):1513-1521. May.
12. Ruiz-Manzano J., Blanquer R., Calpe J.L., Caminero J.A., Caylà J., Domínguez J.A., García J.M., Vidal R. Diagnosis and treatment of tuberculosis. Arch Bronconeumol. 2008, 44(10):551-566. Oct.
13. Tuberculosis surveillance in Europe. (Web:). http://www.ecdc.europa.eu.
14. World Health Organization Global tuberculosis control-surveillance, planning, financing Web:. http://www.who.int.
15. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., Barkhof F., Radue E.W., Jäger H.R., Clifford D.B. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2006, 354(9):924-933. Mar.